

insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442, wherein said antibody immunospecifically binds to a TANGO 268 antigen.

133. (new) The antibody of claim 132, wherein the antibody comprises a variable heavy (VH) CDR having an amino acid sequence of a VH CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

134. (new) The antibody of claim 132, wherein the antibody comprises a variable light (VL) CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

135. (new) The antibody of claim 133, further comprising a VL CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

136. (new) The antibody of claim 134 or 135, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

137. (new) The antibody of claim 136, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

138. (new) The antibody of claim 133, wherein the antibody comprises a VH CDR1 having an amino acid sequence of a VH CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

139. (new) The antibody of claim 138, wherein the VH CDR1 comprises the amino acid sequence of SEQ ID NO:61.

140. (new) The antibody of claim 138 or 139, further comprising a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

141. (new) The antibody of claim 140, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

142. (new) The antibody of claim 133, wherein the antibody comprises a VH CDR2 having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

143. (new) The antibody of claim 142, wherein the VH CDR2 comprises the amino acid sequence of SEQ ID NO:62.

144. (new) The antibody of claim 143, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

145. (new) The antibody of claim 144, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

146. (new) The antibody of claim 133, wherein the antibody comprises a VH CDR3 having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

147. (new) The antibody of claim 146, wherein the VH CDR3 comprises the amino acid sequence of SEQ ID NO:63.

148. (new) The antibody of claim 147, wherein the antibody comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

149. (new) The antibody of claim 148, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

150. (new) The antibody of claim 134, wherein the antibody comprises a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

151. (new) The antibody of claim 150, wherein the VL CDR1 comprises the amino acid sequence of SEQ ID NO:64.

152. (new) The antibody of claim 150 or 151, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

153. (new) The antibody of claim 152, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

154. (new) The antibody of claim 150, wherein the antibody further comprises a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

155. (new) The antibody of claim 154, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

156. (new) The antibody of claim 155, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

157. (new) The antibody of claim 134, wherein the antibody comprises a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

158. (new) The antibody of claim 157, wherein the VL CDR2 comprises the amino acid sequence of SEQ ID NO:65.

159. (new) The antibody of claim 157 or 158, wherein the antibody further comprises a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

160. (new) The antibody of claim 159, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

161. (new) The antibody of claim 138 further comprising a VH CDR2 domain having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

162. (new) The antibody of claim 138 further comprising a VH CDR3 domain having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

163. (new) The antibody of claim 138 further comprising:

- (a) a VH CDR2 having an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VH CDR3 having an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

164. (new) The antibody of claim 138 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

165. (new) The antibody of claim 138 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

166. (new) The antibody of claim 135 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

167. (new) The antibody of claim 166, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

168. (new) The antibody of claim 138 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

169. (new) The antibody of claim 138 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

170. (new) The antibody of claim 169, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

171. (new) The antibody of claim 138 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and

(b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

172. (new) The antibody of claim 171, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

173. (new) The antibody of claim 138 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

174. (new) The antibody of claim 173, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

175. (new) The antibody of claim 142 further comprising a VH CDR3 having the amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

176. (new) The antibody of claim 142 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

177. (new) The antibody of claim 142 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

178. (new) The antibody of claim 142 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

179. (new) The antibody of claim 178, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

180. (new) The antibody of claim 142 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

181. (new) The antibody of claim 142 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

182. (new) The antibody of claim 181, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

183. (new) The antibody of claim 142 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and

(b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

184. (new) The antibody of claim 183, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

185. (new) The antibody of claim 142 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

186. (new) The antibody of claim 185, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

187. (new) The antibody of claim 146 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

188. (new) The antibody of claim 146 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

189. (new) The antibody of claim 146 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

190. (new) The antibody of claim 189, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

191. (new) The antibody of claim 146 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

192. (new) The antibody of claim 146 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

193. (new) The antibody of claim 192, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

194. (new) The antibody of claim 146 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

195. (new) The antibody of claim 194, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

196. (new) The antibody of claim 146 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442;
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

197. (new) The antibody of claim 196, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

198. (new) The antibody of claim 161, further comprising a VL CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

199. (new) The antibody of claim 198, wherein the VL CDR is a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

200. (new) The antibody of claim 198, wherein the VL CDR is a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

201. (new) The antibody of claim 198, wherein the VL CDR is a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

202. (new) The antibody of claim 201, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

203. (new) The antibody of claim 199 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

204. (new) The antibody of claim 203, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

205. (new) The antibody of claim 200 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

206. (new) The antibody of claim 205, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

207. (new) The antibody of claim 199, further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

208. (new) The antibody of claim 207, further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

209. (new) The antibody of claim 208, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

210. (new) The antibody of claim 162, further comprising a VL CDR having an amino acid sequence of a VL CDR encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

211. (new) The antibody of claim 210, wherein the VL CDR is a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

212. (new) The antibody of claim 210, wherein the VL CDR is a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

213. (new) The antibody of claim 210, wherein the VL CDR is a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

214. (new) The antibody of claim 213, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

215. (new) The antibody of claim 211, further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

216. (new) The antibody of claim 212, further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

217. (new) The antibody of claim 216, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

218. (new) The antibody of claim 211 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

219. (new) The antibody of claim 218, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

220. (new) The antibody of claim 218 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

221. (new) The antibody of claim 220, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

222. (new) The antibody of claim 163 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

223. (new) The antibody of claim 163 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

224. (new) The antibody of claim 163 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

225. (new) The antibody of claim 224, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

226. (new) The antibody of claim 163 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

227. (new) The antibody of claim 163 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and

(b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

228. (new) The antibody of claim 227, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

229. (new) The antibody of claim 163 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

230. (new) The antibody of claim 229, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

231. (new) The antibody of claim 163 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

232. (new) The antibody of claim 231, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

233. (new) The antibody of claim 175 further comprising a VL CDR1 domain having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

234. (new) The antibody of claim 175 further comprising a VL CDR2 domain having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

235. (new) The antibody of claim 175 further comprising a VL CDR3 domain having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

236. (new) The antibody of claim 235, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

237. (new) The antibody of claim 175 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

238. (new) The antibody of claim 175 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

239. (new) The antibody of claim 238, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

240. (new) The antibody of claim 175 further comprising:

- (a) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (b) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

241. (new) The antibody of claim 240, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

242. (new) The antibody of claim 175 further comprising:

- (a) a VL CDR1 having an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442
- (b) a VL CDR2 having an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442; and
- (c) a VL CDR3 having an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

243. (new) The antibody of claim 242, wherein the VL CDR3 comprises the amino acid sequence of SEQ ID NO:66.

244. (new) The antibody of claim 132 wherein the CDR comprises the amino acid sequence of SEQ ID NO:66.

245. (new) The antibody of claim 244 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2443.

246. (new) The antibody of claim 244 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

247. (new) The antibody of claim 244 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2445.

248. (new) The antibody of claim 245 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

249. (new) The antibody of claim 247 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2443.

250. (new) The antibody of claim 247 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2444.

251. (new) The antibody of claim 248 further comprising a CDR encoded by the cDNA insert of the plasmid deposited by the ATCC® as patent deposit Number PTA-2445.

252. (new) A substantially purified scFv antibody comprising the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442.

253. (new) The antibody of claim 252 wherein the antibody comprises the amino acid sequence of SEQ ID NO:66.

254. (new) A substantially purified antibody that competes with a scFv antibody encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit Number PTA-2442 for binding to a TANGO 268 antigen.

255. (new) The antibody of claim 254 wherein the antibody comprises the amino acid sequence of SEQ ID NO:66.

256. (new) The antibody of claim 137, wherein the antibody is a monoclonal antibody.

257. (new) The antibody of claim 137, wherein the antibody is a human antibody.

258. (new) The antibody of claim 137, wherein the antibody is a humanized antibody.

259. (new) The antibody of claim 137, wherein the antibody is a Fab fragment.

260. (new) The antibody of claim 137, wherein the antibody is an scFv.

261. (new) The antibody of claim 137, wherein the antibody is conjugated to a therapeutic or drug moiety.

262. (new) The antibody of claim 137, wherein the antibody is conjugated to a detectable substance.

263. (new) A pharmaceutical composition comprising the antibody of claim 137 and a pharmaceutically acceptable carrier.

264. (new) A kit comprising the antibody of claim 137 and instructions for use, in one or more containers.

REMARKS

At the outset, Applicants thank Examiners Huynh, Chan, and Stanton for the courtesies extended during the interviews held May 3, 2001, July 31, 2001, and August 30, 2001, respectively. The claims presented herein reflect the discussions that took place during the interviews with Examiners Chan and Stanton.